NCT04188574 - A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

December 6, 2022

Study Completion Date

June 28, 2023

Conditions

Distal Subungual OnychomycosisFungal InfectionFungus, Nail

Interventions

DRUG

BB2603-1

Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine

DRUG

BB2603-3

Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine

DRUG

BB2603-10

Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine

OTHER

Vehicle

Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.

Trial Locations (20)

Dermatovenerologická klinika VFN, Prague

Sanatorium prof. Arenbergera, Prague

Licca Clinical Research Institute, Augsburg

Praxis Dr. med. Thomas Wildfeuer & Kolleg*innen, Berlin

Hautzentrum Jahrhunderthaus Gemeinschaftspraxis Dres. Niesmann und Othlinghaus, Bochum

Uniklink Carl Gustav Carus, Klinik und Polyklinik für Dermatologie, Dresden

Hautarztpraxis Dres. Leitz, Stuttgart

Centroderm GmbH, Wuppertal

NZOZ Dermal, Bialystok

NZOZ Osteo-Medic, Bialystok

Klinika Dermatologii, Wenerologii, Gdansk

Centrum Medyczne Angelius Provita, Katowice

Gyncentrum Osrodek Badan Klinicznych, Katowice

ETG Lodz, Lodz

Etg Lublin Kunickiego, Lublin

ETG Siedlce, Siedlce

Laser Clinic, Szczecin

ETG Warszawa, Warsaw

dermMedica, Wroclaw

ETG Zamość, Zamość